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3 (Slc22a8) Knockout Mice: A Gender Specific Impact of Reduced
Folates
Adam L. VanWert1 and Douglas H. Sweet1,2
1Department of Pharmaceutical Sciences, Medical University of South Carolina, 280 Calhoun Street
(Rm. QE218)P.O. Box 250140 Charleston, South Carolina 29425, USA.
Abstract
Purpose—To elucidate the role of the renal basolateral transporter, Oat3, in the disposition of
methotrexate.
Materials and Methods—Chinese hamster ovary cells expressing mouse Oat3 were used to
determine kinetics and specificity of inhibition of methotrexate transport. Methotrexate clearance
was then examined in vivo in wildtype and Oat3 knockout mice.
Results—NSAIDs, ß-lactams, and uremic toxins inhibited mOat3-mediated methotrexate uptake
by 70–100%, while folate, leucovorin, and 5-methyltetrahydrofolate inhibited transport by 25–50%.
A Km of 60.6±9.3 μM for methotrexate transport was determined. Oat3 knockout mice exhibited
reduced methotrexate-to-inulin clearance ratios versus wildtype. Male wildtype mice, but not
knockouts or females, demonstrated significantly accelerated methotrexate clearance in response to
reduced folates. Reduced folates also markedly inhibited hepatic methotrexate accumulation in
males, but not females, and the response was independent of Oat3 function.
Conclusions—Oat3 contributes to methotrexate clearance, but represents only one component
responsible for methotrexate's elimination. Therefore, in patients, dysfunctional hOAT3
polymorphisms or drug competition for hOAT3 transport may severely impact methotrexate
elimination only when redundant means of methotrexate removal are also compromised.
Furthermore, the present findings suggest that reduced-folate administration only influences
methotrexate disposition in males, with the renal reduced-folate response influenced by OAT3
function.
Keywords
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INTRODUCTION
Methotrexate (MTX) is a commonly employed chemotherapeutic agent prescribed for various
cancers and rheumatic diseases (1). The therapeutic and detrimental cytotoxic effects of this
folate antimetabolite are linked to its ability to potently compete with folic acid metabolism,
resulting in impaired DNA synthesis and thus reduced cell proliferation (2). In order for MTX
to act as a folate antimetabolite, it must first reach the intracellular dihydrofolate reductase
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enzyme (3,4). Being an organic anion, cellular entry of MTX is dependent upon transport
mechanisms in plasma membranes, which are pivotal for efficient entry of charged molecules
into the cell (2,5,6). Thus, interpatient variability in both toxic and therapeutic responses to
MTX is potentially caused, in part, by interpatient variability in organic anion transport
mechanisms (7). This variability may result from differences in transporter expression/function
(e.g., polymorphisms) or transporter burden (i.e., MTX-substrate interactions).
Many different transporters have been shown to interact with MTX in vitro (Table I). Based
on these in vitro findings, carriers that can transport MTX include organic anion transporters
(OAT) 1 to 4 (5-13), multi drug resistance-associated proteins (MRP) 1 to 4 (8-11), the reduced
folate carrier (RFC-1; 12,13), organic anion transporting polypeptide (OATP) 1A2 (14), and
OAT-K1/K2 (15,16). Since MTX's major route of elimination is renal, and it is substantially
bound to plasma protein (1), renal secretion of MTX plays an important role in its elimination
and nephrotoxicity. Pivotal to secretion is proximal tubular basolateral transport, a function
that depends on an array of carrier proteins including the basolateral organic anion exchangers
Oat1 and Oat3 (17,18). Experiments using renal slices, a model system which tracks basolateral
uptake across a native renal proximal tubule epithelium, indicate that the most likely
contributors to renal basolateral MTX transport are Oat3 and RFC-1 (13). These transporters
both have relatively strong affinities for MTX (Table I) and it has been suggested that they
play equal roles in MTX uptake in rat kidney; together accounting for the majority of basolateral
MTX uptake into proximal tubular cells (13).
Various drugs that interact with human OAT3 (hOAT3) in vitro, e.g., penicillins, probenecid,
and nonsteroidal anti-inflammatory drugs (NSAIDs), have been shown to elevate the blood
level of MTX in patients when administered concomitantly (1). The reduced folate, leucovorin
(5-formyltetrahydrofolate), is administered after termination of MTX therapy to rescue patients
from the cytotoxic effects of MTX and is a substrate for basolateral hRFC-1 (19). However,
studies in rats indicate that instead of reducing MTX renal elimination through competition on
rRFC-1, leucovorin stimulates MTX renal elimination, possibly by exchanging for MTX on
an apical transporter(s; 20). Further studies are necessary to determine which transporters are
responsible in vivo for drug interactions and interpatient variability in MTX elimination and
toxicity.
As mentioned previously, hOAT3 interacts relatively strongly with MTX in vitro (Table I).
Moreover, a number of human OAT3 polymorphisms have been identified and shown to yield
transport proteins of marked functional heterogeneity (21). With some mutants, substrate
specificity is altered, and with others, transport is completely abolished (21). Taken together,
this suggests hOAT3 substrate competition and/or polymorphisms as underlying causes of
variability in MTX elimination and nephrotoxicity in vivo. Thus, in the present study, substrate
competition on, and kinetics of MTX transport by, murine Oat3 was determined in vitro. This
information was then used to design in vivo experiments in wildtype and Oat3 knockout mice
to directly examine the role of Oat3 in the elimination and distribution of MTX, as well as in
MTX-reduced folate interactions.
MATERIALS AND METHODS
Isolation of Stably Transfected Cell Lines
The pBlue-scriptSK/Roct (mOat3) vector containing the full-length murine Oat3 (Roct) cDNA
clone (GenBank Accession no. AF078869) was a generous gift from Dr. David R. Beier (22).
The mOat3 plasmid was transformed into Escherichia coli, amplified, and purified according
to standard laboratory protocols. All manipulations were done in accordance with the
procedures outlined by the Medical University of South Carolina Institutional Biosafety
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Committee registration for infectious agents and recombinant DNA (IBC#2123-9 and
IBC#2123-10, reapproved 02/01/2007).
CHO-FlpIn cells were purchased from Invitrogen (Carlsbad, CA) and maintained at 37°C with
5% CO2 in Ham's F12 medium (Mediatech, Inc., Herndon, VA) containing 10%
SerumSupreme (Cambrex, Walkersville, MD) and 100 μg/ml zeocin (Invitrogen). Isolation of
the control “mock” transfected cell line stably transformed with the empty pcDNA5/FRT
vector (CHO-FRT cells) has been described previously (23). The experimental line stably
transformed with a pcDNA5/FRT-mOat3 vector, designated CHO-mOat3 cells, was made for
this study. Briefly, the pcDNA5/FRT-mOat3 vector was constructed by gel isolating the ~2.0
kbp full-length mOat3 Sal1-Not1 fragment from the pBluescriptSK/mOat3 vector and ligating
it into Sal1-Not1 cut pcDNA5/FRT vector. For transfection, cells (2×105) were plated into
individual wells of a six well culture plate and grown overnight. Cells were transfected with 1
μg pcDNA5/FRT-mOat3 DNA and 8 μg pOG44 DNA overnight at 37°C using Transfectin
Lipid Reagent (2 μl Transfectin/μg DNA; Bio-Rad, Hercules, CA). After 24 h the medium was
replaced with fresh medium containing 500 μg/ml hygromycin B (Invitrogen). Cell clones were
selected with 500 μg/ml hygromycin B for 4 weeks and maintained in 125 μg/ml hygromycin
B after testing positive for organic anion transport activity.
Cell Transport Assays
Cells (2×105 per well) were seeded in 24-well tissue culture plates and grown for 2 days (37°
C, 5% CO2) in the absence of antibiotics. Before initiation of transport experiments, the culture
medium was removed and the cells were equilibrated for 10 min with transport buffer (Hanks'
balanced salt solution containing 10 mM HEPES, pH 7.4; Sigma-Aldrich, Saint Louis, MO).
The equilibration medium was removed before a final application of 500 μl of transport buffer
containing 10–500 μM [3H]MTX (0.5 μCi/ml) in the absence or presence of inhibitors (1 mM)
as indicated. After incubation at room temperature for the indicated times, the uptake solution
was removed and the cells were rinsed rapidly three times with 1 ml of ice-cold transport buffer.
The cells were dissolved in 500 μl of 1 M NaOH and neutralized with 50 μl of 10 M HCl.
Aliquots were removed and analyzed for protein content using a BCA protein assay kit (Pierce,
Rockford, IL) and by liquid scintillation counting. Uptake was calculated as picomoles of
substrate per mg of protein. Transformations for kinetic calculations were performed using
GraphPad Prism software, and the Km was calculated from the x intercept of the Lineweaver–
Burk plot. All experiments were repeated three times in triplicate to confirm results.
Animals
Wildtype and Oat3 knockout age-matched C57BL/6 mice (10–16 weeks old) were used in the
present study. Mice were allowed food and water ad libitum and were housed in animal
facilities maintained by the Medical University of South Carolina Division of Laboratory
Animal Resources. The MUSC program for laboratory animal care has an assurance statement
on file with the NIH Office for the Protection from Research Risks/Department of Health and
Human Services and has maintained full accreditation with the Association for Assessment
and Accreditation of Laboratory Animal Care since 1987. All animal procedures were
approved by the MUSC Institutional Animal Care and Use Committee (AR#2082, reapproved
9/1/2006).
Plasma Elimination and Organ Distribution
Wildtype and Oat3 knockout mice were administered 100 μCi/kg [3H]MTX and 10 μCi/kg
[14C]inulin concomitantly by bolus tail vein injection with normal saline as vehicle (total
injection volume was 5 μl per gram of mouse weight). Unlabeled MTX with or without
combined reduced folates (5-methyltetrahydrofolate with leucovorin at a tenfold molar excess
over MTX) were included in the bolus injection in the indicated experiments to test the effect
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of MTX dose and reduced folates on elimination. The MTX dose in “clinical dose” experiments
was 1.7 mg/kg, yielding an initial plasma level of ~20 μM [10–1,000 μM is commonly observed
in humans (1)]. Serial blood samples (~35 ml) were obtained at 1, 5, 10, 15, 20, and 30 min,
and were centrifuged to obtain plasma. At 30 min, the mice were sacrificed and organs were
harvested, rinsed, blotted, weighed, and homogenized prior to scintillation spectroscopy.
Samples were counted in a Packard Tri-Carb 2900 TR liquid scintillation counter with external
quench correction and microcuries were converted to moles of substrate. For each experiment,
an aliquot of the freshly prepared stock [3H]MTX/[14C]inulin injection solution was counted
in order to determine the exact μCi/μg of MTX and inulin. This afforded accurate
determinations of MTX and inulin plasma concentrations as well as the precise MTX and inulin
doses to enter into the WinNonlin® program for pharmacokinetic calculations.
Pharmacokinetic and Statistical Analyses
Plasma clearance determinations were performed using WinNonlin® software (Pharsight
Corporation, Mountain View, CA). Two-compartment IV-bolus modeling was used with micro
constants (pharmacokinetic model #7) and resulted in the lowest coefficients of variation for
kinetic parameters as compared to other models. Statistical significance of elimination curves
was determined using two-way ANOVA and posthoc analyses were not conducted. The
student's t test was used for all other comparisons. The α for significance is 0.05.
Materials
Unlabeled MTX was acquired from MP Biomedicals (Solon, OH) and [3H]MTX (12 Ci/mmol)
was acquired from Moravek Biochemicals (Brea, CA). [3H]Estrone-3-sulfate (50 Ci/mmol)
and [14C]inulin (0.0095 Ci/mmol) were acquired from American Radiolabeled Chemicals
(Saint Louis, MO). Folic acid, folinic acid (leucovorin), and 5-methyltetrahydrofolate (5-
CH3-THF) were acquired from Sigma-Aldrich (Saint Louis, MO). All other reagents were
purchased from standard sources. Structures of all chemicals can be obtained from their
suppliers' websites.
RESULTS
mOat3-mediated Transport of MTX In Vitro
mOat3-mediated uptake of estrone-3-sulfate in CHO-mOat3 cells was ~22 times greater than
nonspecific uptake (Fig. 1). Accumulation of MTX was ~fourfold greater than control (Fig.
1). Uptake of both compounds was completely inhibited by 1 mM probenecid. The background
MTX signal in Chinese hamster ovary cells was low. The timecourse of MTX uptake into
CHO-mOat3 cells indicated that cellular accumulation was linear for the first 10 min (Fig. 2a).
Therefore, kinetic measurements were determined using a 5 min uptake duration. Fig. 2b
demonstrates saturable uptake of MTX into CHO-mOat3 cells and linear nonspecific
accumulation in CHO-FRT cells. Fig. 2c illustrates the Lineweaver–Burk transformation for
determining transport kinetic values. The calculated Km from three experiments is 60.6±9.3
μM.
Various classes of organic anions markedly inhibited mOat3-mediated MTX uptake (Fig. 3),
including NSAIDs (salicylate and indomethacin), uremic toxins (uric acid and indoxyl sulfate),
neurotransmitter metabolites (dihydroxyphenylacetic acid and hydroxyindoleacetic acid), ß-
lactam antibiotics (penicillin G), sulfated steroid hormone conjugates (estrone-3-sulfate), and
prototypical organic anion transporter substrates/inhibitors (p-aminohippurate, probenecid,
and bromosulfophthalein). Folate and two reduced folates, leucovorin and 5-
methyltetrahydrofolate, exhibited differential potencies for inhibition of mOat3 (Fig. 3). Folate
and 5-methyltetrahydrofolate each inhibited mOat3-mediated MTX transport by ~50%,
whereas leucovorin demonstrated less than 30% inhibition, each at a concentration 100 times
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greater than that of MTX. The cation, tetraethylammonium, did not significantly inhibit MTX
transport on mOat3 (Fig. 3).
In Vivo Plasma Elimination of MTX in Wildtype and Oat3 Knockout Mice
Male wildtype and Oat3 knockout mice exhibited similar plasma levels of MTX to each other
at both tracer and “clinical” doses (Fig. 4a and b). When administered concomitantly with
reduced folates, MTX plasma levels were significantly elevated in Oat3 knockout males as
compared to wildtype (Fig. 4c). Inulin plasma levels were not significantly different between
male wildtype and Oat3 knockout mice for all MTX treatments studied (Fig. 4d–f).
In contrast, female Oat3 knockout mice had significantly elevated plasma levels of MTX at
the “clinical” dose compared to wildtype mice (Fig. 5a). When administered concomitantly
with reduced folates, MTX plasma levels were similar between wildtype and Oat3 knockout
females (Fig. 5b). Inulin plasma levels were not significantly different between female wildtype
and Oat3 knockout mice for either of the treatment conditions studied (Fig. 5c and d).
In order to control for possible interanimal variation in hemodynamics and glomerular
filtration, the MTX-to-inulin clearance ratio was calculated separately for each mouse (Fig. 6).
Two different comparisons are presented (wildtype versus Oat3 knockout mice and male
versus female mice) using the same data. For all conditions, MTX plasma clearance was greater
than inulin plasma clearance (i.e., clearance ratio >1.0). The mean inulin plasma clearance
value for all mice in this investigation was 13.57±0.64 ml min−1 kg−1 (n=30). Male Oat3
knockout mice exhibited a reduced clearance ratio with tracer, but not “clinical,” MTX dose
as compared to wildtype mice (Fig. 6a). In contrast, the clearance ratio was significantly
reduced in female Oat3 knockout mice given “clinical” dose MTX (Fig. 6a). Concomitant
reduced-folate administration increased the MTX-to-inulin clearance ratio in male wildtype
mice, but not in female wildtype mice or Oat3 knockout mice of either gender (Fig. 6a). Female
wildtype mice demonstrated a greater MTX-to-inulin clearance ratio than male wildtype mice,
but no gender differences were observed for any other comparisons (Fig. 6b).
In Vivo Distribution of MTX in Wildtype and Oat3 Knockout Mice
MTX concentrated in the liver and kidneys of male and female mice of both genotypes 30 min
after IV bolus administration (Fig. 7). However, testes, ovaries, skeletal muscle, and brain all
exhibited tissue-to-plasma MTX ratios less than 1 (Fig. 7). In the presence of reduced folates,
male Oat3 knockout mice demonstrated significantly reduced liver, testes, and brain tissue-to-
plasma MTX ratios compared to wildtype mice. In marked contrast to male knockout animals,
female Oat3 knockout mice demonstrated significantly reduced liver, kidney, and brain tissue-
to-plasma MTX ratios only in the absence of reduced folates (Fig. 7). Female wildtype, but
not Oat3 knockout, mice exhibited reduced tissue-to-plasma MTX ratios in the liver and
kidneys in response to reduced-folate inhibition (Fig. 7).
Absolute renal and hepatic accumulation was also assessed in order to identify inherent organ
differences in MTX accumulation under the different conditions (Fig. 8). Male wildtype mice
exhibited a substantial reduction in renal MTX accumulation in response to reduced folates,
while there was little to no response to reduced folates by male Oat3 knockout and female mice
of both genotypes (Fig. 8a). Male wildtype and Oat3 knockout mice exhibited markedly
reduced liver accumulation of MTX in response to reduced folates (Fig. 8b). While significance
was not achieved in male wildtype mice, when male wildtype and Oat3 knockout liver data
are pooled together, the effect of reduced folates is more significant than in knockouts alone
(from a p value of <0.05 (KO) to a p value of <0.01 (pooled)). In stark contrast to males, but
similar to the renal response observed in females, hepatic accumulation in female mice was
virtually unresponsive to reduced folates (Fig. 8b). For Oat3 knockout animals, plasma levels
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were similar within genders comparing the presence and absence of reduced folates (Figs. 4
and 5), indicating that differences in kidney and liver accumulation were not simply due to
differences in blood levels, but inherent differences in the organs themselves.
DISCUSSION
MTX is a commonly used cancer chemotherapeutic and antirheumatic agent. It is effective in
treating breast, lung, and bone cancer, as well as leukemia, and is considered the “gold”
standard for treatment of rheumatoid arthritis (1). While this pharmacotherapeutic has
benefited many patients, its cytotoxic effects are nonspecific and detrimental to healthy cells,
as is the case with the majority of cancer chemotherapeutics. The disposition of MTX, and
therefore its toxicity, is influenced by drug interactions reportedly involving transport proteins
in barrier epithelia (1,7). The majority of MTX is eliminated renally in humans as the parent
compound within 24 h after an IV dose (80–90%), with substantial plasma protein binding
placing a large burden on renal active secretory mechanisms (1). Alterations in renal proximal
tubular secretion of MTX can therefore affect MTX systemic levels and nephrotoxicity.
An essential component of renal net secretion is baso-lateral uptake, a process that depends on
transport proteins in the plasma membrane. MTX's interaction with two renal basolateral
transporters, human OAT3 and RFC-1, is substantial in vitro (24–26), indicating that these
exchangers may be important sources of variable MTX pharmacokinetics between patients and
under different substrate burden scenarios (e.g., polypharmacy with interacting drugs). Of
pivotal relevance to this is the recent discovery of human polymorphisms in an ethnically
diverse population resulting in heterofunctional hOAT3 protein (21). Out of the ten distinct
protein-altering variants identified, three resulted in complete loss of hOAT3 function, and
others resulted in significantly reduced function, when assessed for estrone-3-sulfate and
cimetidine transport (21). The observation that some OAT3 polymorphisms present in humans
result in completely non-functional transporter protein highlights the importance of
determining the consequences of OAT3 dysfunction in an intact organism.
Previous characterization of MTX transport in heterologous Oat3 expression systems has been
limited to the human and rat orthologs (13,24,25). Therefore, prior to in vivo analyses, we
sought to determine the specificity and kinetics of MTX transport on mOat3. It was observed
that MTX interacts with mOat3 much like hOAT3, and all compounds tested that are known
to inhibit hOAT3 also inhibited mOat3 (Fig. 3;27). The known OAT3/Oat3 inhibition profile
suggests that the numerous MTX-drug interaction case reports in humans may be mediated, in
part, by competition on hOAT3 (1). However, drug interactions with MTX involving
transporters are also likely to occur on the apical aspect of renal proximal tubule cells, as well
as hepatically, and in other barrier membranes (Table I). To this regard, it has been shown that
NSAIDs interfere with MTX transport by the apically-targeted hMRP2 and hMRP4 (8), and
MTX is transported by apical hOAT4 and rOAT-K1/K2 (25,28).
Interestingly, in the current study, three known substrates of hRFC-1, folate, leucovorin, and
5-methyltetrahydrofolate, also inhibited mOat3, providing novel information regarding the
specificities of these compounds for renal basolateral transporters. Folate and leucovorin have
not previously been assessed for their ability to interact with Oat3 orthologs, but 5-
methyltetrahydrofolate has been demonstrated to inhibit rOat3 (13). The interaction of folate,
as well as the reduced folates, with mOat3, was weaker than most of the other anions tested.
These findings suggest that, like their analog MTX, folate and the reduced folates may be
substrates for OAT3 and RFC-1, both renal proximal tubular basolateral exchangers. Finally,
MTX uptake in CHO-mOat3 cells was clearly saturable with an estimated Km of 60.6±9.3
μM for mOat3 (Fig. 2b and c), which is comparable to the reported Km for hOAT3 of ~20 mM
(24,25), indicating that mOat3 and hOAT3 have similar affinities for MTX (Table I).
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While MTX has been shown to interact with a vast array of transporters in vitro, current
evidence indicates that rOat3 may play an important role in MTX renal elimination, acting in
parallel with rRFC-1 at the basolateral membrane of renal proximal tubule cells (13). We
therefore sought to determine the in vivo relevance of mOat3 in MTX elimination and
distribution utilizing an Oat3 knockout mouse model (29,30). Collectively, findings from
pharmacokinetic studies indicate that MTX elimination is impaired in Oat3 knockout mice.
When MTX clearance is normalized to that of inulin in order to control for extraneous
differences between animals (e.g., hemodynamic variability; 20), it is apparent that Oat3
knockout mice exhibit a significant, albeit modest, reduction in MTX elimination as compared
to wildtype mice (Fig. 6a). This observation suggests that Oat3 plays a role in MTX elimination
in the intact organism.
MTX clearance was significantly accelerated in male wildtype mice when coadministered with
reduced-folates, but this effect was not observed in male knockout mice or female mice of
either genotype. This observation suggests that female mice are missing a mechanism which
allows reduced folates to stimulate MTX elimination in males. Additionally, it indicates that
the stimulatory effect of reduced folates requires functional Oat3 transporter protein (i.e.,
reduced folates had no effect on elimination in male knockout mice). Accelerated MTX
elimination has been observed before in male rats as a consequence of leucovorin
administration (20), but has not been studied before in females. Although it has been suggested
that leucovorin may exchange for intracellu-lar MTX to stimulate apical efflux (20), the present
findings indicate that the phenomenon is dependent on Oat3 (a basolateral exchanger). Thus,
it is possible that intracellular reduced folates, such as leucovorin, can exchange for
extracellular MTX on basolateral Oat3, stimulating proximal tubular uptake of MTX. In the
present study, it was demonstrated that reduced folates interfere with MTX transport on Oat3
(Fig. 3). On the other hand, female wildtype mice did not demonstrate accelerated MTX
elimination in the presence of reduced folates. Therefore, if Oat3 is being trans-stimulated by
apically acquired reduced folates, perhaps female mice do not accumulate reduced folates from
the apical aspect as efficiently as males.
Finally, female wildtype mice exhibit significantly greater MTX clearance than male wildtype
mice, but the difference is abolished by Oat3 deletion (Fig. 6b). This indicates that female mice
may have greater Oat3 function than males. In a previous study, gender differences in Oat3
mRNA expression were reported in mice, but no clear differences were observed in the C57BL/
6 strain (31). Investigations in our laboratory indicate that female wildtype C57BL/6 mice
express Oat3 mRNA at a level twice as high as males (data not shown), potentially leading to
greater Oat3 protein expression. Unfortunately, current tools are not robust enough to
investigate mouse Oat3 protein levels.
In order to determine the impact of deletion of Oat3 on the distribution of MTX, its
accumulation was measured in various organs. At 30 min after its administration, MTX
concentrated in the liver and kidneys of mice, but not in the testes, ovaries, skeletal muscle, or
brain, reflecting active uptake into liver and kidney (Fig. 7). The liver-to-plasma MTX ratio
was four to five times higher than the kidney-to-plasma MTX ratio in wildtype mice at 30 min,
despite the fact that MTX is eliminated primarily renally, suggesting that the residence time
of MTX in the liver is greater than in the kidneys. Absolute renal and hepatic MTX levels were
also plotted in order to determine inherent differences in the organs (Fig. 8). The observation
that kidney levels of MTX were markedly reduced in wildtype, but not Oat3 knockout, males
in response to reduced folates (Fig. 8a) agrees with the heightened clearance observed under
these conditions (Fig. 6a), and indicates that renal residence time of MTX may be shortened
in wildtype males, but not Oat3 knockouts, when administered reduced folates. This
observation in wildtype male mice agrees with a previous report in male rats (20). However,
the observation that females are virtually unresponsive to reduced folate administration, with
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respect to MTX disposition, has not been previously reported. Additionally, the discovery that
Oat3 knockout males do not respond to reduced folates, with respect to renal accumulation, as
do wildtype males, suggests that the stimulatory effect on reduced folate clearance is dependent
on Oat3 function. Therefore, Oat3 possibly facilitates stimulation of renal secretion by reduced
folates. The finding that male mice are sensitive to inhibition by reduced folates, with respect
to liver accumulation, but female mice exhibit a minimal response, indicates that an inherent
difference exists within the liver itself, between genders. Since absolute liver accumulation
was similar between males and females in the absence of reduced folates, but exhibited a large
gender difference in response to reduced folates, it appears that males and females have evolved
hepatic transport functions of equal efficiency, but differential mechanisms, at least for MTX.
CONCLUSION
In conclusion, the present findings suggest that mouse Oat3 interacts with MTX much like the
human ortholog with respect to transport kinetics and drug interactions. Furthermore, folate
and reduced folates can cis-inhibit MTX transport on mOat3. Deletion of Oat3 resulted in
significantly impaired MTX clearance in mice. Therefore, compromised human OAT3,
whether resulting from protein-altering single-nucleotide polymorphisms or from drug
substrate overload (e.g., polypharmacy involving NSAIDs, penicillins, or urico-surics such as
probenecid), may not substantially impact MTX elimination unless redundant means of
removal are also impaired. Future investigations are necessary to dissect out the individual
roles of each carrier in multifactorial MTX secretory transport. In addition to elucidating the
role of Oat3 in MTX disposition, this investigation also highlighted major gender differences
in mice with respect to MTX reduced folate drug–drug interactions. Males appear to have both
an Oat3-dependent renal MTX secretory mechanism and an Oat3-independent hepatic MTX
transport mechanism that are sensitive to reduced folates, which females are lacking.
Regardless of Oat3's role in total plasma clearance of MTX, this renal basolateral exchanger
likely plays a substantial role in mediating methotrexate proximal tubular neph-rotoxicity, as
a previous investigation found that rOat3 is responsible for approximately 50% of renal
basolateral MTX uptake (13). Thus, it is possible that concomitant hOAT3 substrate
administration can reduce the nephrotoxic effects of MTX. Of course, this action may raise the
systemic level of MTX if a compound with renal transporter multispecificity is used, e.g., an
NSAID inhibiting OATs and MRPs, a consequence that has been observed previously in
humans (1). Therefore, with careful monitoring, it may be feasible for clinicians to reduce the
MTX dose used in their patients by coadministration of an Oat3 substrate, resulting in a reduced
potential for nephrotoxicity, but therapeutic plasma levels.
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ABBREVIATIONS
5-CH3-THF 5-methyltetrahydrofolate
5-CHO-THF 5-formyltetrahydrofolate (a.k.a. folinic acid or leucovorin)
5-HIAA 5-hydroxyindoleacetic acid
CHO-FRT Chinese hamster ovary cells transfected with empty vector
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CHO-mOat3 Chinese hamster ovary cells transfected with murine organic anion
transporter 3
DOPAC dihydroxyphenylacetic acid
h human
Km the Michaelis–Menten constant
m mouse
MRP multidrug resistance-associated protein
MTX methotrexate
NSAIDs non-steroidal anti-inflammatory drugs
OAT or Oat human or non-human organic anion transporter, respectively
r rat
RFC-1 reduced folate carrier 1
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Fig. 1.
Transport of estrone-3-sulfate and MTX by murine Oat3. Uptake was measured for 10 min at
room temperature in Chinese hamster ovary cells stably transfected with mOat3 (CHO-mOat3)
or empty vector (CHO-FRT). a Uptake of [3H]estrone-3-sulfate (5 μM) in the presence or
absence of probenecid (1 mM). b Uptake of [3H]MTX (1 μM) in the presence or absence of
probenecid (1 mM). Asterisks represent significant differences from respective mOat3 control
uptake (***, p<0.001). Values are mean±SE.
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Fig. 2.
Timecourse and Michaelis–Menten Kinetics of MTX transport in CHO-mOat3 cells. a Uptake
of [3H]MTX (1 μM) was measured for 1, 2, 5, 10, 30, and 90 min at room temperature in CHO-
mOat3 and CHO-FRT cells in order to determine the linear accumulation phase. b Uptake of
[3H]MTX (10, 25, 100, 250, and 500 μM) was measured for 5 min at room temperature in
CHO-mOat3 and CHO-FRT cells in order to construct a saturation curve. The “corrected”
curve was obtained by subtracting the background nonspecific uptake as measured in the CHO-
FRT cells from mOat3-mediated uptake. c Lineweaver–Burk plot of the “corrected” uptake
values. The estimated Km calculated from three independent experiments conducted in
triplicate is 60.6±9.3 μM. Values are mean±SE.
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Fig. 3.
Inhibition profile of organic anions competing with MTX transport in CHO-mOat3 cells.
Uptake of [3H]MTX (10 μM) in CHO-mOat3 cells was measured for 10 min at room
temperature in the presence (1 mM) or absence of organic anions, and the organic cation
tetraethylammonium. Background in CHO-FRT cells was determined in the absence of
inhibitor. Asterisks represent significant differences from CHO-mOat3 control (*, p<0.05; **,
p<0.01; ***, p<0.001). Abbreviations: DOPAC (dihydroxyphenylacetic acid), 5-HIAA (5-
hydroxyindoleacetic acid), 5-CHO-THF (5-formyltetrahydrofolate), and 5-CH3-THF (5-
methyltetrahydrofolate). Values are mean±SE.
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Fig. 4.
Plasma elimination of MTX in male wildtype and Oat3 knockout mice in the presence or
absence of reduced folates. a Plasma elimination of [3H]MTX after a 2.45 μg/kg dose. b Plasma
elimination of [3H]MTX after a 1.7 mg/kg dose. c Plasma elimination of [3H]MTX (1.7 mg/
kg) in the presence of a tenfold molar excess of 5-methyltetrahydrofolate and 5-
formyltetrahydrofolate (leucovorin). d–f Plasma elimination of [14C]inulin injected
concomitantly with [3H]MTX (charts correspond vertically). Asterisks represent significant
differences between the entire elimination curves using two-way ANOVA (**, p<0.01).
Significant differences were present between the curves in c only. N=3 animals for each curve
and values given are mean±SE. Note: units on y-axis of a are ng/ml.
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Fig. 5.
Plasma elimination of MTX in female wildtype and Oat3 knockout mice in the presence or
absence of reduced folates. a Plasma elimination of [3H]MTX after a 1.7 mg/kg dose. b Plasma
elimination of [3H]MTX (1.7 mg/kg) in the presence of a tenfold molar excess of 5-
methyltetrahydrofolate and 5-formyltetrahydrofolate (leucovorin). c and d Plasma elimination
of [14C]inulin injected concomitantly with [3H]MTX (charts correspond vertically).
Asterisks represent significant differences between the entire elimination curves using two-
way ANOVA (**, p<0.01). Significant differences were present between the curves in a only.
N=3 animals for each curve and values given are mean±SE.
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Fig. 6.
MTX-to-inulin plasma clearance ratio comparing genotypes and genders. Ratios were
determined using MTX and inulin plasma clearance values for each individual mouse. The
mean inulin plasma clearance value for all mice in this investigation is considered typical (13.57
±0.64 ml min−1 kg−1, n=30). a Comparison between wildtype (WT) and Oat3 knockout (KO)
mice in the presence (denoted as+folates) or absence of reduced folates. b Comparison between
male and female mice in the presence or absence of reduced folates. Asterisks represent
significant differences between genotypes (a) and genders (b) or any other indicated bars (*,
p<0.05). Clearance values were generated from the data used in Figs. 4 and 5. N=3 animals for
each bar and values given are mean±SE. All ratios are calculated from data obtained in the
“clinical dose” (i.e., 1.7 mg/kg) methotrexate experiments with the exception of “low dose”
for males, which was obtained using data from the tracer dose experiment.
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Fig. 7.
Tissue-to-plasma ratio of MTX in wildtype and Oat3 knockout mice in the presence or absence
of reduced folates. Thirty minutes after IV bolus [3H]MTX (Figs. 4 and 5) in the presence or
absence of reduced-folate inhibition, the indicated tissues were harvested and [3H]MTX levels
were quantified. Thirty-minute plasma MTX levels were used to calculate the tissue-to-plasma
ratios. Asterisks represent significant differences between wildtype and Oat3 knockout mice
given the same treatment (i.e., with or without reduced-folate inhibition), and for the same
tissue and gender (*, p<0.05; **, p<0.01). Daggers represent significant differences between
mice of the same genotype in the presence or absence of folates (†, p<0.05; ‡, p<0.01). Values
are mean±SE.
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Fig. 8.
Absolute kidney and liver accumulation of MTX in wildtype and Oat3 knockout mice. Thirty
minutes after IV bolus [3H]MTX (Figs. 4 and 5) in the presence or absence of reduced folates,
kidneys (a) and liver (b) were harvested and [3H]MTX levels were quantified. WT, wildtype
mice; KO, Oat3 knockout mice; –, absence of folates; +, presence of folates. Asterisks represent
significant differences between the indicated bars (*, p<0.05). N=3 animals and values given
are mean±SE.
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Table I
MTX Transport Kinetics in Heterologous Expression Systems
Transporter Expression System Km±SE (μM) Reference
hOAT1 Xenopus oocyte 724±74.9 (24)
S2 MRPTCa 553.8±43.2 (25)
rOat1 LLC-PK1 cells 14.9±0.8 (13)
hOAT3 Xenopus oocyte 17.2±3.6 (24)
10.9±1.7 (32)
S2 MRPTCa 21.1±2.8 (25)
mOat3 CHO cells 60.6±9.3 Current study
hOAT4 S2 MRPTCa 17.8±1.6 (25)
hMRP2 HEK293 cell membrane vesicles 480±90 (8)
hMRP4 HEK293 cell membrane vesicles 220±70 (8)
rRfc-1 MDCKII cells 17.8±1.8 (13)
hOATP1A2 Xenopus oocyte 457±118 (14)
rOat-K1 MDCK cells 2.1b (16)
LLC-PK1 cells 1.0b (15)
rOat-K2 MDCK cells 1.8b (16)
Species abbreviations: h Human, r rat, m mouse
a
Immortalized mouse renal S2 proximal tubule cell line stably transfected with the indicated transporter.
b
Standard errors were not reported.
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